Mary Coleman - Johnson Johnson Independent Director
| JNJ Stock | MXN 2,485 0.48 0.02% |
Director
Dr. Mary Sue Coleman, Ph.D. is an Independent Director of the company. She joined the Board of Directors in 2003 and is a member of the Audit Committee and the Science, Technology Sustainability Committee. She is President Emerita of the University of Michigan, having served as President from August 2002 to July 2014. She also was a Professor of Biological Chemistry in the University of Michigan Medical School and a Professor of Chemistry in the University of Michigan College of Literature, Science and the Arts. From 1995 to July 2002, Dr. Coleman served as President of the University of Iowa. Prior to 1995, Dr. Coleman served as Provost and Vice President for Academic Affairs at the University of New Mexico, Vice Chancellor for Graduate Studies Research and Associate Provost and Dean of Research at the University of North Carolina at Chapel Hill, and a member of the biochemistry faculty and an administrator at the Cancer Center of the University of Kentucky in Lexington. Elected to the National Academy of Sciences Institute of Medicine in 1997, Dr. Coleman is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Coleman is a Trustee of the Gerald R. Ford Foundation, the Gates Cambridge Scholarship program, and the Mayo Clinic Foundation, and is on the Board of Directors of The Kavli Foundation. since 2003.
| Age | 70 |
| Tenure | 21 years |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset (ROA) of 0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Fernando Lopez | Grupo Sports World | 35 | |
| Judy Bruner | Applied Materials | 59 | |
| Patricia Menendez | Grupo Sports World | N/A | |
| Henry Meyer | United Airlines Holdings | 64 | |
| Ivanhoe Donaldson | Micron Technology | N/A | |
| Robert Coretz | Air Transport Services | 54 | |
| Carolyn Corvi | United Airlines Holdings | 66 | |
| Robert Milton | United Airlines Holdings | 55 | |
| Wilfrido Mejorada | Grupo Sports World | N/A | |
| Sito Pantoja | United Airlines Holdings | 61 | |
| Laura Peterson | Air Transport Services | 58 | |
| Hadi Ibrahim | Grupo Sports World | 42 | |
| Victor Garcia | Grupo Sports World | N/A | |
| Hector Rivero | Grupo Sports World | N/A | |
| Yvonne McGill | Applied Materials | N/A | |
| Laurence Simmons | United Airlines Holdings | 69 | |
| Humberto Herrera | Grupo Sports World | 46 | |
| John Walker | United Airlines Holdings | 57 | |
| Walter Isaacson | United Airlines Holdings | 65 | |
| Mark Heil | Micron Technology | 52 | |
| Richard Baudouin | Air Transport Services | 66 | |
Management Performance
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0881 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| William Perez, Independent Director | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
| Mary Coleman, Independent Director | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Ex CFO | ||
| Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Mary Beckerle, Independent Director | ||
| Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee | ||
| Scott Davis, Director | ||
| Louise Mehrotra, Vice President Investor Relations | ||
| Robert Decker, Controller Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| James Swanson, Ex Officer | ||
| D Davis, Independent Director | ||
| Hubert Joly, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Jessica Moore, VP Relations | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Eugene Washington, Independent Director | ||
| Elizabeth Forminard, Exec Counsel | ||
| Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Susan Lindquist, Independent Director | ||
| Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0881 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 9.15 T | |||
| Shares Outstanding | 2.61 B | |||
| Shares Owned By Insiders | 0.09 % | |||
| Shares Owned By Institutions | 70.93 % | |||
| Price To Earning | 28.71 X | |||
| Price To Book | 6.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to Invest in Johnson Johnson guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |